National Institutes of Health, a Component of the US Dept. of Health & Human Services

Institute for Research in Biomedicine

Yongping Yang

Baoshan Zhang

Peter D Kwong

Ivelin Georgiev

Michael Gordon Joyce

Guillaume Stewart-Jones

John R Mascola

Tongqing Zhou

Gwo-Yu Chuang

Aliaksandr Druz

Barney S Graham

Marie Pancera

Mallika Sastry

Yaroslav Tsybovsky

Man Chen

Gary J Nabel

Antonio Lanzavecchia

Davide Corti

Cheng Cheng

Jeffrey C Boyington

Mark Connors

Gilad Ofek

Jason Gorman

Cinque Soto

Jiang Zhu

Rebecca S Rudicell

Ulrich Baxa

Masaru Kanekiyo

Wing-Pui Kong

Li Ou

Paul Thomas

Joseph Van Galen

Peter L Collins

Ursula J Buchholz

Jason Scott McLellan

Zhi-yong Yang

John Mascola

Young Do Kwon

Wei Shi

Xueling Wu

Jinghe Huang

Leo Laub

Lei Chen

Sanjay Srivatsan

Emily Rundlet

Priyamvada Acharya

Rita Chen

Kai Xu

Syed M Moin

Rebecca M Lynch

Wing-pui Kong

Rui Kong

Kevin Liu

Hui Geng

Yen-Ting Lai

Jason S Mclellan

Ivelin Stefanov Georgiev

Rebecca Lynch

Leo B Laub

Gary Nabel

Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.

Prefusion PIV F immunogens and their use

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.

Prefusion RSV F proteins and their use

Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.

Recombinant metapneumovirus f proteins and their use

HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.

Recombinant HIV-1 envelope proteins and their use

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.

Self-assembling insect ferritin nanoparticles

Recombinant metapneumovirus F proteins and their use

Substitutions-modified prefusion RSV F proteins and their use

Immunogens comprising a recombinant HIV-1 Env ectodomain trimer stabilized in a prefusion closed conformation and methods of their use and production are disclosed. In several embodiments, the immunogen can be used to elicit an immune response to HIV-1 in a subject.

Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens

Growing community of inventors

Potomac, MD, United States of America

Yongping Yang